To the Editor
We do not agree with many comments made by Davern and colleagues 1 regarding the performance comparisons of their monoclonal serum free light chain (FLC) assay with the polyclonal Freelite assay (The Binding Site, Birmingham, England) and welcome the opportunity to respond.
The authors stated that the Freelite assay missed some λ molecule subgroups. During the 8-year commercial availability of Freelite, there have been millions of these tests used in patients and hundreds of peer-reviewed publications from independent groups. During this period, many studies have found 100% diagnostic sensitivity for Freelite in patients with both κ and λ light chain only multiple myeloma. 2 In contrast, only 1 study has shown that Freelite failed to recognize monoclonal FLCs, and that was in a single patient. 3 The urine monoclonal light chain (Bence Jones protein [BJP] ) from the patient was subsequently included in the immunization protocols 3 years ago, and it was recognized by subsequent antiserum batches. Freelite specificity is, therefore, validated against thousands of cases vs the 71 reported by Davern et al. 1 Indeed, the higher specificity of the Freelite assay is actually demonstrated in their own results zFigure 1z. Figure 1 demonstrates that there is a nonlinear relationship between the results using the different assays, indicating these are not calibration differences, as suggested. Three patients (cases 6, 9, and 11) had known urine λ BJPs and, therefore, were expected to have increased serum λ FLCs. With the Freelite assay, all 3 had raised λ FLC levels with abnormal κ/λ ratios. Yet with the enzyme-linked immunosorbent assay (ELISA), the samples had normal or low λ FLC values and only had abnormal ratios owing to suppressed κ FLC levels. This is strongly suggestive of inadequate specificity. In comparison, for both κ assays, the 3 patients with reported κ BJPs had raised serum κ concentrations, indicating similar specificity for the 2 assays.
The authors also stated that Freelite assays showed interference from intact monoclonal immunoglobulins. However, the cited study had wrongly investigated antisera manufactured for immunofixation rather than the nephelometry-specific Freelite-grade antisera. [4] [5] [6] Indeed, Davern et al 1 did not demonstrate adequate specificity for their own assay. In normal serum, there is approximately 1,000-fold more intact immunoglobulin with bound light chains than FLCs, but in their competitive ELISA, they only challenged with a 10-fold excess. Potential cross-reaction is in evidence by their 5-fold higher ELISA normal range The Authors' Reply We regret that Legg et al do not agree with many of our comments regarding comparison of the performance of our monoclonal antibody (mAb)-based free light chain (FLC) assay 1 with that of the Freelite kit, which uses extensively absorbed, affinity-purified polyclonal reagents; this is understandable given the commercial nature of their product. Despite the plethora of publications attesting to the clinical value of FLC measurements in patients with clonal plasma cell-related disorders that use kits furnished by Freelite's manufacturer (The Binding Site), concerns have been raised about the specificity of their polyclonal antibodies and the reproducibility and accuracy of the assays. [2] [3] [4] [5] In addition, there is disagreement between results derived using this procedure and those obtained by Nakano et al 6, 7 with their mAb-based ELISA. Figure 1 , provided by Legg et al, is misleading: Patients 3, 6, 9, 10, and 11 (all of whom had a serum IgG λ, a urinary λ BJP, or both components) had a predominant λ FLC ratio owing to enhanced synthesis of the clonal λ FLCs (as well as low or reduced concentrations of normal κ FLCs). In contrast with the Freelite anti-FLC polyclonal reagents, our anti-free κ and λ mAbs exhibit no cross-reactivity with IgG or IgA, even (as shown in zFigure 2z) when challenged with a 1,000-fold excess of these molecules. We posit that the exquisite sensitivity and capability of our anti-FLC mAbs to recognize all of the known human light chain isotypes and allotypes account for the quantitative differences and nonlinearity of the results obtained with the Freelite reagents as given in Table 4 of our article. 1 In addition to cross-reaction with IgG and other serum immunoglobulins, other confounding factors that can affect the reliability of the nephelometricbased Freelite assay are the presence of light-scattering aggregates in serum samples, the concentration of covalent LC dimers, 7 errors introduced as a result of serum dilution, variations in information obtained using the different types
